{"id":"W4225464106","doi":"10.1002/cncr.34180","title":"Conditional survival and long‐term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma","year":2022,"lang":"en","type":"article","venue":"Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":263,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Cancer Agency","funders":"Cilag; University of Texas MD Anderson Cancer Center; Genentech; Ipsen; PharmaMar; European Society for Medical Oncology; Shionogi; Astellas Pharma; Eisai; Halozyme; Mirati Therapeutics; National Institutes of Health; Mylan; Arrowhead Pharmaceuticals; Les Laboratories Pierre Fabre; Incyte; Pfizer; Daiichi Sankyo Europe; National Cancer Institute; LEO Pharma; Intuitive Surgical; Merck KGaA; Taiho Pharmaceutical; Memorial Sloan-Kettering Cancer Center; Celgene; PTC Therapeutics; Exelixis; Sanofi; Amgen; EUSA Pharma; AstraZeneca; Ono Pharmaceutical; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Ipilimumab; Sunitinib; Hazard ratio; Nivolumab; Renal cell carcinoma; Internal medicine; Clinical endpoint; Oncology; Progression-free survival; Kidney cancer; Proportional hazards model; Survival analysis; Randomized controlled trial; Cancer; Overall survival; Confidence interval; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001921028,0.0003187806,0.000809597,0.0002089955,0.0002230739,0.0005179381,0.000324563,0.0003595023,0.001372141],"category_scores_gemma":[0.001725766,0.0001383944,0.001176108,0.0001899315,0.0003339292,0.000567976,0.0003165096,0.0009413267,0.0001270826],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007444761,"about_ca_system_score_gemma":0.0007318186,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005717202,"about_ca_topic_score_gemma":0.001295501,"domain_scores_codex":[0.999553,0.0001898211,0.00003869772,0.00008587429,0.00007154357,0.0000610323],"domain_scores_gemma":[0.9987903,0.0003878484,0.0004245945,0.00005251211,0.00004068408,0.000304034],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.6897002,0.00747712,0.1342662,0.0008226655,0.003921082,0.0001136809,0.0002335496,0.009181307,0.007569512,0.0003515926,0.00135384,0.1450092],"study_design_scores_gemma":[0.09225407,0.369797,0.5000587,0.0001730103,0.006144359,0.0005697805,0.0001704936,0.01987368,0.006757364,0.001088729,0.003014351,0.0000985499],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9981478,0.001239373,0.00009185795,0.000091301,0.0000187597,0.00003069723,0.00008711547,0.000007319208,0.0002857455],"genre_scores_gemma":[0.9994536,0.0001888644,0.0000816316,0.00004047016,0.00002259505,0.00002719771,0.0001031772,8.885855e-7,0.00008150691],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001921028,"threshold_uncertainty_score":0.01015949,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0191062222688187,"score_gpt":0.2543971519995092,"score_spread":0.2352909297306905,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}